OUTFRONT Media Announces Quarterly Dividend
NEW YORK, May 8, 2025 /PRNewswire/ — OUTFRONT Media Inc. (NYSE: OUT) announced today that its board of directors has declared a quarterly cash dividend on... Read more.
Avidity Biosciences Reports First Quarter 2025 Financial Results and Recent Highlights
On track to deliver key regulatory updates for del-brax and topline data from dose escalation cohorts in the FORTITUDE™ trial in the second quarter Positive topline... Read more.
EY launches new solution to evolve and accelerate enterprise operations with SAP S/4HANA® Cloud
Accesses deep domain experience and capabilities from EY to help transform critical functions across the entire enterprise. Delivers an EY managed service solution... Read more.
Karyopharm to Report First Quarter 2025 Financial Results on May 12, 2025
— Conference Call Scheduled for Monday, May 12, 2025, at 4:30 p.m. ET — NEWTON, Mass., May 8, 2025 /PRNewswire/ — Karyopharm Therapeutics Inc.... Read more.
Omnicom to Present at the J.P. Morgan Global Technology, Media and Communications Conference
NEW YORK, May 8, 2025 /PRNewswire/ — Omnicom (NYSE: OMC) today announced that it will present at the J.P. Morgan 53rd Annual Global Technology, Media and Communications... Read more.
Research Solutions Reports Fiscal Third Quarter 2025 Results
Reports 23 Percent Increase in ARR to $20.4 Million and 43 Net New Platform Deployments, Positive Net Income and Record Adjusted EBITDA and Cashflow HENDERSON, Nev.,... Read more.
Astrana Health, Inc. Reports First Quarter 2025 Results
Company to Host Conference Call on Thursday, May 8, 2025, at 2:30 p.m. PT/5:30 p.m. ET ALHAMBRA, Calif., May 8, 2025 /PRNewswire/ — Astrana Health, Inc. (“Astrana,”... Read more.
Regulus Therapeutics Reports First Quarter 2025 Financial Results and Recent Updates
Entered into an agreement to be acquired by Novartis for $7.00 per share in cash, with potential to receive an additional $7.00 per share in cash through a... Read more.
Trevi Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates
Completed enrollment and last patient last visit in the Phase 2b CORAL trial in IPF patients with chronic cough; topline results continue to be expected in the second... Read more.
TTEC Announces First Quarter 2025 Financial Results
First Quarter 2025Revenue was $534.2 Million, down 7.4 PercentNet Income was $3.2 Million or 0.6 Percent of Revenue($13.6 Million or 2.6 Percent of Revenue Non-GAAP)Adjusted... Read more.